<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Neuro-Oncology</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-06-10">10 June 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Eskil</forename><surname>Eskilsson</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gro</forename><forename type="middle">V</forename><surname>Rosland</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Krishna</forename><forename type="middle">M</forename><surname>Talasila</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stian</forename><surname>Knappskog</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Olivier</forename><surname>Keunen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrea</forename><surname>Sottoriva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sarah</forename><surname>Foerster</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gergely</forename><surname>Solecki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Torfinn</forename><surname>Taxt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Radovan</forename><surname>Jirik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sabrina</forename><surname>Fritah</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><forename type="middle">N</forename><surname>Harter</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kristjan</forename><surname>Va</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jubayer</forename><surname>Al Hossain</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Justin</forename><forename type="middle">V</forename><surname>Joseph</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Roza</forename><surname>Jahedi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Halala</forename><forename type="middle">S</forename><surname>Saed</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sara</forename><forename type="middle">G</forename><surname>Piccirillo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Inma</forename><surname>Spiteri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Euskirchen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Grazia</forename><surname>Graziani</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Daubon</surname></persName>
						</author>
						<author>
							<persName><roleName>Per</roleName><forename type="first">Morten</forename><surname>Lund-Johansen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Øyvind</forename><surname>Enger</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Winkler</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><forename type="middle">A</forename><surname>Ritter</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Simone</forename><forename type="middle">P</forename><surname>Niclou</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Colin</forename><surname>Watts</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rolf</forename><surname>Bjerkvig</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Hrvoje</forename><surname>Miletic</surname></persName>
							<email>hrvoje.miletic@uib.no</email>
						</author>
						<author>
							<persName><forename type="first">Lina</forename><surname>Leiss</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Biomedicine</orgName>
								<orgName type="institution">University of Bergen</orgName>
								<address>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Clinical Science</orgName>
								<orgName type="department" key="dep2">Department of Oncology</orgName>
								<orgName type="institution">University of Bergen</orgName>
								<address>
									<country>Norway (S.K.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">K.)</orgName>
								<orgName type="department" key="dep2">Department of Oncology</orgName>
								<orgName type="laboratory">Norlux Neuro-Oncology Laboratory</orgName>
								<orgName type="institution">Luxembourg Institute of Health</orgName>
								<address>
									<country key="LU">Luxembourg</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Clinical Pharmacy</orgName>
								<orgName type="department" key="dep2">Institute of Pharmacy</orgName>
								<orgName type="laboratory">Centre for Evolution and Cancer</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country>UK (A.S.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">Ernst-Moritz-Arndt-University</orgName>
								<address>
									<settlement>Greifswald</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Neurooncology</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<settlement>Germany</settlement>
									<region>G.S., F.W.)</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Institute of Scientific Instruments</orgName>
								<orgName type="institution" key="instit2">ASCR</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Goethe-University Medical School</orgName>
								<address>
									<settlement>Frankfurt am Main</settlement>
									<country>Germany (P.N.H.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Department of Clinical Neurosciences</orgName>
								<orgName type="laboratory">Statistics and Computational Biology Laboratory</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<country>UK (S.G.P., C.W.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Department of Experimental Neurology</orgName>
								<orgName type="department" key="dep2">P.E.</orgName>
								<orgName type="department" key="dep3">Department of Systems Medicine</orgName>
								<orgName type="institution" key="instit1">University of Cambridge</orgName>
								<orgName type="institution" key="instit2">UK (I.S.)</orgName>
								<orgName type="institution" key="instit3">Charite ´-Universita ¨tsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="institution">University of Rome «Tor Vergata»</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">Department of Neurosurgery</orgName>
								<orgName type="institution" key="instit1">U1029 -University of Bordeaux</orgName>
								<orgName type="institution" key="instit2">Alle ´e Geoffroy St. Hilaire</orgName>
								<address>
									<settlement>Pessac</settlement>
									<country>France (T.D.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<addrLine>Jonas Lies vei 65</addrLine>
									<postCode>5021</postCode>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Department of Biomedicine</orgName>
								<orgName type="institution">University of Bergen</orgName>
								<address>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">Department of Clinical Science</orgName>
								<orgName type="department" key="dep2">Department of Oncology</orgName>
								<orgName type="institution">University of Bergen</orgName>
								<address>
									<country>Norway (S.K.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">K.)</orgName>
								<orgName type="department" key="dep2">Department of Oncology</orgName>
								<orgName type="laboratory">Norlux Neuro-Oncology Laboratory</orgName>
								<orgName type="institution">Luxembourg Institute of Health</orgName>
								<address>
									<settlement>Luxembourg</settlement>
									<region>O.K., S.F., S.P.N., R.B.)</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="laboratory">Centre for Evolution and Cancer</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country>UK (A.S.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department of Clinical Pharmacy</orgName>
								<orgName type="department" key="dep2">Institute of Pharmacy</orgName>
								<orgName type="institution">Ernst-Moritz-Arndt-University</orgName>
								<address>
									<settlement>Greifswald</settlement>
									<country>Germany (S.F., C.A.R.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="department">Department of Neurooncology</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<settlement>Germany</settlement>
									<region>G.S., F.W.)</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="institution" key="instit1">Institute of Scientific Instruments</orgName>
								<orgName type="institution" key="instit2">ASCR</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Goethe-University Medical School</orgName>
								<address>
									<settlement>Frankfurt am Main</settlement>
									<country>Germany (P.N.H.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff25">
								<orgName type="department">Department of Clinical Neurosciences</orgName>
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<region>H.M.)</region>
									<country>Norway (J.A.H</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff26">
								<orgName type="laboratory">Statistics and Computational Biology Laboratory</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<country>UK (S.G.P., C.W.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff27">
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<country>UK (I.S.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff28">
								<orgName type="department">Department of Experimental Neurology</orgName>
								<orgName type="institution" key="instit1">Neuro Clinic</orgName>
								<orgName type="institution" key="instit2">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff29">
								<orgName type="department" key="dep1">P.E.</orgName>
								<orgName type="department" key="dep2">Department of Systems Medicine</orgName>
								<orgName type="institution">Charite´ -Universita¨tsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff30">
								<orgName type="institution">University of Rome «Tor Vergata»</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff31">
								<orgName type="department">Department of Neurosurgery</orgName>
								<orgName type="institution" key="instit1">U1029 -University of Bordeaux</orgName>
								<orgName type="institution" key="instit2">Alle´e Geoffroy St. Hilaire</orgName>
								<address>
									<settlement>Pessac</settlement>
									<country>France (T.D.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff32">
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Neuro-Oncology</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-06-10">10 June 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">90ABF918672172892DB194B97C444C9D</idno>
					<idno type="DOI">10.1093/neuonc/now113</idno>
					<note type="submission">Received 25 October 2015; accepted 13 March 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>angiogenesis</term>
					<term>EGFR</term>
					<term>EGFRvIII</term>
					<term>glioblastoma</term>
					<term>invasion</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background.</s><s>Amplification of the epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are among the most common genetic alterations in glioblastoma (GBM), the most frequent and most aggressive primary brain tumor.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods.</head><p><s>In the present work, we analyzed the clonal evolution of these major EGFR aberrations in a small cohort of GBM patients using a unique surgical multisampling technique.</s><s>Furthermore, we overexpressed both receptors separately and together in 2 patient-derived GBM stem cell lines (GSCs) to analyze their functions in vivo in orthotopic xenograft models.</s></p><p><s>Results.</s><s>In human GBM biopsies, we identified EGFR amplification as an early event because EGFRvIII mutations emerge from intratumoral heterogeneity later in tumor development.</s><s>To investigate the biological relevance of this distinct developmental pattern, we established experimental model systems.</s><s>In these models, EGFR + tumor cells showed activation of classical downstream signaling pathways upon EGF stimulation and displayed enhanced invasive growth without evidence of angiogenesis in vivo.</s><s>In contrast, EGFRvIII + tumors were driven by activation of the prototypical Src family kinase c-Src that promoted VEGF secretion leading to angiogenic tumor growth.</s></p><p><s>Conclusions.</s><s>The presented work shows that sequential EGFR amplification and EGFRvIII mutations might represent concerted evolutionary events that drive the aggressive nature of GBM by promoting invasion and angiogenesis via distinct signaling pathways.</s><s>In particular, c-SRC may be an attractive therapeutic target for tumors harboring EGFRvIII as we identified this protein specifically mediating angiogenic tumor growth downstream of EGFRvIII.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma</head><p><s>EGFR amplification, which is detected in 30% -40% of tumors, remains among the most frequently occurring focal genetic aberrations observed in primary GBM. <ref type="bibr" target="#b0">1</ref> EGFRvIII, a mutant EGF receptor overexpressed in 50% -60% of EGFR-amplified GBMs, lacks the extracellular ligand-binding domain (exons 2 -7 deletion) and is constitutively active. <ref type="bibr" target="#b1">2</ref> EGFRvIII alone has no transforming capacity, but it can contribute to the transformation of normal cells in the context of other mutations. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref></s><s>enetic heterogeneity within tumors likely contributes to the failure of molecular-targeted therapies in cancer treatment. <ref type="bibr">5 -7</ref></s><s>urgical multisampling of GBM, in addition to recent advances in sequencing technology, has revealed profound heterogeneity within individual tumors, even at the single cell level. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref></s><s>For instance, a recent study using single-cell nucleus sequencing showed intratumoral heterogeneity of a rare EGFR mutant (EGFRvII), while EGFR amplification was found in all tumor cells. <ref type="bibr" target="#b9">10</ref></s><s>At present, it is unclear to what extent this heterogeneity accounts for the more frequently occurring EGFRvIII mutation, which we addressed in a small cohort of GBM patients in the present study.</s></p><p><s>Invasion and angiogenesis are hallmarks of GBM, and a number of studies have shown that both wtEGFR and EGFRvIII can activate these growth processes in malignant and normal cells. <ref type="bibr">11 -21</ref></s><s>However, the majority of these studies focused on only one of the receptors.</s><s>Thus, there is an urgent need to study both receptors within one model system in vivo to accurately identify their functions within GBM development.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Recruitment and Sample Collection</head><p><s>This project received approval from the UK National Research Ethics Service and the University of Cambridge National Health Service Foundation Trust Research &amp; Development department.</s><s>Details are described in Supplementary methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Copy Number Analyses</head><p><s>Assessments of EGFR copy number changes (gene amplifications) were performed as described in Supplementary methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identification of EGFR Deletions</head><p><s>Intragenic deletions of EGFR exons 2 -7 were identified by longrange PCR amplifications covering the regions of potential breakpoint (intron 1 and intron 7).</s><s>PCRs were performed using the Qiagen Long Range PCR kit according to the manufacturer's instructions and using the primers described previously. <ref type="bibr" target="#b22">22</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Screening for EGFR Point Mutations</head><p><s>Point mutations in the EGFR gene were assessed by PCR amplification of exons 2-7 with subsequent capillary sequencing of the resulting PCR products.</s><s>Details are described in Supplementary methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell Culture</head><p><s>Cells from the human GBM biopsy (referred to as P3) were passaged 20 times in nude rats, as previously described. <ref type="bibr" target="#b23">23</ref></s><s>CH421k denotes cells derived from a biopsy of another patient, as previously described, <ref type="bibr" target="#b24">24</ref> and were kindly provided by Dr. Christel Herold-Mende (University of Heidelberg, Germany).</s><s>Cells were cultured in Neurobasal (NB) medium as previously described. <ref type="bibr" target="#b25">25</ref></s><s>NB medium with bFGF is a complete medium (NBM).</s><s>The human embryonic kidney cell line 293T and human glioma cell line U87 were obtained and maintained, as previously described. <ref type="bibr" target="#b26">26</ref></s><s>Unless otherwise indicated, all cell lines were grown at 378C in a humidified atmosphere of 5% CO 2 .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Molecular Cloning</head><p><s>The cloning of EGFRvIII, wtEGFR, shSrc, and constitutive active Src (Src + ) are described in Supplementary methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Lentiviral Vector Production and Transduction of Glioblastoma Cells</head><p><s>Lentiviral vectors carrying wtEGFR, EGFRvIII, shSRC, or Src + were produced and titrated in NBM as previously described. <ref type="bibr" target="#b26">26</ref></s><s>3 and NCH421k cells were transduced with lentiviral vectors as previously described. <ref type="bibr" target="#b26">26</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Flow Cytometric Analysis and Cell Sorting</head><p><s>Flow cytometric analyses were performed on an Accuri-6 flow cytometer (BD Biosciences).</s><s>Subsequent data analysis was performed using FlowJo software (Tree Star Inc.).</s><s>Details are described in Supplementary methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In Vitro Signaling Complex Immunocapture Mass Spectrometry</head><p><s>The procedures were performed as previously described. <ref type="bibr" target="#b27">27</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In Vivo Experiments</head><p><s>Nude immunodeficient rats (rnu/rnu Rowett) were fed a standard pellet diet and provided with water ad libitum.</s><s>Animal procedures were approved by the Norwegian National Animal Research Authority.</s><s>Details are described in Supplementary methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemistry</head><p><s>Immunohistochemistry of paraffin sections was performed as previously described. <ref type="bibr" target="#b28">28</ref></s><s>Antibody dilutions are described in Supplementary methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western Blotting</head><p><s>Protein was extracted from tumor tissue in lysis buffer (Kinexus), and electrophoresis and blotting were performed as previously described. <ref type="bibr" target="#b23">23</ref></s><s>Antibody dilutions are described in Supplementary methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Magnetic Resonance Imaging</head><p><s>MRI was performed and analyzed based on methods described previously. <ref type="bibr" target="#b29">29</ref></s><s>Perfusion and permeability parameters were calculated as previously described <ref type="bibr" target="#b30">30</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>Survival was analyzed by a log-rank test based on the Kaplan-Meier test using SPSS software.</s><s>Differences between pairs of groups were determined with the Student t test.</s><s>Statistical significance of changes between perfusion, permeability, and contrast-enhancement parameters in the MRI study was assessed by Wilcoxon rank-sum tests using Matlab (Math-Works, Inc).</s><s>Individual pixels were used as observations.</s><s>P values , .05 were considered significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The Evolutionary Dynamics of EGFR Amplification and EGFRvIII Mutation in Glioblastoma</head><p><s>To characterize the clonal evolution of EGFR aberrations, we studied EGFR-amplified GBMs because only these tumors also carry the EGFRvIII mutation.</s><s>We analyzed 3 GBMs harboring EGFR amplification using a unique surgical multisampling technique, as previously described. <ref type="bibr" target="#b7">8</ref></s><s>This approach enabled us to address intratumoral heterogeneity of EGFR aberrations (Fig. <ref type="figure" target="#fig_0">1A</ref>).</s><s>EGFR gain/amplification was present in all tumor regions in all patients, while EGFRvIII, which was detected in 2 patients, exhibited regional differences (Fig. <ref type="figure" target="#fig_0">1A</ref>; Supplementary material, Table <ref type="table">S1</ref>).</s><s>Interestingly, EGFRvIII was found in 3 different tumor areas (T1, T2, and S) from patient sp54 (Fig. <ref type="figure" target="#fig_0">1A  and B</ref>; Supplementary material, Table <ref type="table">S1</ref>).</s><s>DNA breakpoint analysis revealed the same breakpoint for areas T1 and T2; however, a different breakpoint was observed in area S (Fig. <ref type="figure" target="#fig_0">1B</ref>), indicating parallel evolution of different subclones in the tumor.</s><s>A similar pattern was observed in a second patient (sp55) showing EGFRvIII mutations in the 2 areas (T4 and T) with 2 different DNA breakpoints (Fig. <ref type="figure" target="#fig_0">1A and B</ref>).</s><s>In the same patient, a hotspot EGFR point mutation (R222C) within the extracellular domain was found in a mutually exclusive fashion in samples T2 and S (Fig. <ref type="figure" target="#fig_0">1A</ref>; Supplementary material, Table <ref type="table">S1</ref>).</s><s>We also performed molecular clock analysis of these 2 patients, as previously described, <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32</ref> and integrated the clonal evolution of EGFR mutations that appeared in distinct subclones over time (Fig. <ref type="figure" target="#fig_0">1C</ref>).</s><s>These results strongly suggest that EGFRvIII mutations (i) show intratumoral heterogeneity and (ii) develop from EGFR-amplified tumor clones during tumor progression.</s><s>To establish biological relevance of the distinct clonal evolution patterns of wtEGFR and EGFRvIII, we investigated the functions of both receptors in clinically relevant animal models.</s><s>We used GSCs from 2 different EGFRvIII-negative human GBM biopsies with minimal (P3) or undetectable (NCH421k) wtEGFR expression (Supplementary material, Fig. <ref type="figure" target="#fig_0">S1A</ref>).</s><s>NCH421k cultures and xenografts from P3 were previously characterized genetically. <ref type="bibr" target="#b25">25,</ref><ref type="bibr" target="#b26">26</ref></s><s>We modified the cell lines to overexpress either wtEGFR (wtEGFR + ), EGFRvIII (EGFRvIII + ), or both receptors together (wtEGFR + EGFRvIII + ) using lentiviral vectors.</s><s>Transduced cells were sorted using fluorescence-activated cell sorting (FACs) to achieve high purity (Supplementary material, Fig. <ref type="figure" target="#fig_0">S1B</ref>).</s></p><p><s>To define the growth and angiogenic properties of the different cell populations in vivo, we injected the modified cell populations and parental control cells derived from both patients separately into the brains of nude rats.</s><s>Kaplan-Meier survival analysis revealed significantly shorter survival for animals with EGFRvIII + and wtEGFR + EGFRvIII + tumors compared with controls and those with wtEGFR + tumors (Fig. <ref type="figure" target="#fig_1">2A</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_1">S2A</ref>).</s><s>There was no significant difference in survival between animals harboring wtEGFR + and animals with control tumors for either of the 2 xenograft models (Fig. <ref type="figure" target="#fig_1">2A</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_1">S2A</ref>).</s></p><p><s>We performed MRI with and without contrast agent to characterize angiogenesis.</s><s>In xenografts from both patients, EGFRvIII + and wtEGFR + EGFRvIII + tumors revealed more angiogenesis as observed by increased contrast enhancement compared with control and wtEGFR + tumors (Fig. <ref type="figure" target="#fig_1">2B</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_1">S2B</ref>).</s><s>These results indicate that EGFRvIII, but not wtEGFR, fosters angiogenic tumor growth.</s><s>We characterized additional MRI parameters by using dynamic contrast enhancing (DCE)-MRI.</s><s>We assessed blood volume (Bv), blood flow (F), volume transfer coefficient (Ktrans), and interstitial space (Ve).</s><s>These parameters are indicators of perfusion and vascular permeability representing the angiogenic propensities of the tumors.</s><s>EGFRvIII + and wtEGFR + EGFRvIII + tumors from both xenografts showed significantly greater values for all 4 parameters compared with both wtEGFR + and control tumors (Fig. <ref type="figure" target="#fig_1">2C</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_1">S2C</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histologic and Molecular Analyses Confirm Increased Angiogenesis by EGFRvIII</head><p><s>To substantiate the imaging results, we performed histological, immunohistochemical (IHC), and molecular analysis of tumor specimens derived from the xenografts.</s><s>Histology confirmed highly angiogenic tumors with microvascular proliferations and/or necrosis in the EGFRvIII + and wtEGFR + EGFRvIII + groups from both xenograft models, while control and wtEGFR + tumors were less angiogenic (Fig. <ref type="figure" target="#fig_2">3A</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_2">S3A</ref>).</s><s>This was further verified and quantified by vWF immunohistochemistry (Fig. <ref type="figure" target="#fig_2">3A and B</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_2">S3A and B</ref>).</s><s>To confirm the difference in angiogenesis at the molecular level, we performed Western blots of HIF1A and a panel of important proangiogenic factors.</s><s>EGFRvIII + and wtEGFR + EGFRvIII + P3 tumors demonstrated upregulation of HIF1A as well as the angiogenic factors VEGFA and angiopoietin 1 and 2 compared with both control and wtEGFR + P3 tumors, which exhibited minimal expression of these proteins (Fig. <ref type="figure" target="#fig_2">3C</ref>).</s><s>HIF1A and VEGFA were also upregulated in EGFRvIII + and wtEGFR + EGFRvIII + NCH421k tumors compared with control and wtEGFR + tumors (Supplementary material, Fig. <ref type="figure" target="#fig_2">S3C</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>EGFRvIII Correlates With Increased Angiogenesis in Glioblastoma Patient Samples</head><p><s>To validate the results from our xenograft models in patients, we selected 3 specimens with robust EGFRvIII expression from several EGFR-amplified GBM biopsies.</s><s>Importantly, these specimens showed activated EGFR (pEGFR + ) in areas that did not express EGFRvIII, corresponding with activation of wtEGFR.</s><s>Tumor sections were immunostained for vWF to investigate vessel size and to quantify vessel area.</s><s>EGFRvIII + tumor cells were frequently found around microvascular proliferations and dilated tumor vessels, while EGFRvIII 2 /pEGFR + areas contained smaller vessels (Fig. <ref type="figure" target="#fig_2">3D</ref>).</s><s>Quantification of vessel area per microscopic field (HPF) revealed significantly greater values for EGFRvIII + areas compared with EGFRvIII 2 /pEGFR + areas, which confirmed induction of angiogenesis by EGFRvIII but not by wtEGFR (Fig. <ref type="figure" target="#fig_2">3E</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>wtEGFR, but not EGFRvIII, Promotes Invasion of Glioblastoma Cells</head><p><s>We have previously shown that wtEGFR promotes invasion of EGFR-amplified glioblastoma cells. <ref type="bibr" target="#b26">26</ref></s><s>To further validate these findings in the present models, we analyzed invasion of the different P3 and NCH421k cell populations in vivo.</s><s>We observed an increased capacity of wtEGFR + tumor cells from both patients to invade into the brain parenchyma compared with EGFRvIII + , wtEGFR + EGFRvIII + , and control tumor cells (Supplementary material, Fig. <ref type="figure" target="#fig_3">S4A</ref>).</s><s>EGFRvIII + tumors showed more circumscribed growth and were even less invasive than control tumors.</s><s>The results were verified by quantification of nestin + invading cells into the cortex (Supplementary material, Fig. <ref type="figure" target="#fig_3">S4B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>c-SRC Is Upregulated and Activated in EGFRvIII + Tumors</head><p><s>Since the results presented above point at different biological functions of EGFRvIII and wtEGFR we hypothesized that this was due to differential activation of downstream-signaling pathways.</s><s>To further explore this hypothesis, we used signalingcomplex immunocapture mass spectrometry <ref type="bibr" target="#b27">27</ref> to generate signaling network analyses of wtEGFR + and EGFRvIII + P3 cells with and without EGF stimulation.</s><s>wtEGFR showed strong interaction with adaptor proteins corresponding to classical RTK signaling, particularly Erk signaling (Fig. <ref type="figure" target="#fig_3">4A</ref>; Supplementary material, Table <ref type="table">S2</ref>).</s><s>This result confirms observations from previous studies implicating Erk as a major contributor to cell migration upon EGF stimulation. <ref type="bibr" target="#b33">33,</ref><ref type="bibr" target="#b34">34</ref></s><s>In contrast to wtEGFR, EGFRvIII showed a more intricate interaction scenario in the signaling network analyses, associating with a number of other receptors with oncogenic potential as well as with Src family kinases (SFKs) (Fig. <ref type="figure" target="#fig_3">4A</ref>; Supplementary material, Table <ref type="table">S3</ref>).</s><s>Based on previous Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma observations implicating SFKs in EGFR signaling, <ref type="bibr" target="#b35">35</ref> we decided to explore the role of SFKs in our model.</s></p><p><s>The highly conserved nature of SFK amino acid sequence 36 may prevent accurate distinction of individual SFKs by highthroughput mass spectrometry.</s><s>Thus, in order to validate our findings, we performed Western blots of the prominent SFKs c-SRC, FYN, c-YES, and LYN on lysates from P3 and NCH421k cells differentially expressing wtEGFR and EGFRvIII in vitro.</s><s>Both P3 and NCH421k cells expressed c-SRC and LYN (Supplementary material, Fig. <ref type="figure" target="#fig_5">S5A</ref>), but we could not detect FYN or c-YES (data not shown).</s><s>All cell groups expressed c-SRC and LYN independent of exogenous EGF stimulation in a heterogeneous fashion, and the cells appeared to upregulate these SFKs in an EGFR-dependent manner.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma</head><p><s>To evaluate the SFK distribution in vivo, we performed immunohistochemistry to detect different SFKs in P3 and NCH421k tumor xenograft specimens (Fig. <ref type="figure" target="#fig_3">4B</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_5">S5B</ref>).</s><s>Both xenografts showed staining for c-SRC, LYN, and c-YES.</s><s>Expression of c-SRC was profoundly upregulated in EGFRvIII + tumors compared with control and wtEGFR + tumors (Fig. <ref type="figure" target="#fig_3">4B</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_5">S5B</ref>).</s><s>LYN was expressed in tumor cells and the vasculature, but it was expressed heterogeneously in both P3 and NCH421 across all tumor groups (Fig. <ref type="figure" target="#fig_3">4B</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_5">S5B</ref>).</s><s>c-YES, meanwhile,   was not expressed in tumor cells and was rather contained to the vascular compartment.</s><s>Indeed, EGFRvIII + tumors showed more pronounced staining of c-YES as these tumors exhibit enhanced angiogenesis (Fig. <ref type="figure" target="#fig_3">4B</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_5">S5B</ref>).</s></p><p><s>To confirm our findings by a second method, we performed Western blots on control, wtEGFR + , and EGFRvIII + P3 tumor lysates (Fig. <ref type="figure" target="#fig_3">4C</ref>; Supplementary material, Fig. <ref type="figure" target="#fig_5">S5C</ref>).</s><s>The blots were consistent with immunostaining as c-SRC expression was substantially upregulated only in EGFRvIII + tumor lysates.</s><s>c-SRC activation, as determined by phosphorylation at both tyrosine 216 and 419, was also greater in lysates from EGFRvIII + tumors.</s><s>Furthermore, consistent with our previous findings, the angiogenic factors bFGF and VEGFA were upregulated only in lysates from EGFRvIII + tumors compared with lysates from control and wtEGFR + tumors.</s></p><p><s>To validate that c-Src is expressed and activated in patient tumors expressing EGFRvIII, we stained consecutive sections of 5 EGFRvIII + patient biopsies with EGFRvIII and Src antibodies.</s><s>As shown in Fig. <ref type="figure" target="#fig_3">4D, c</ref>-SRC is expressed in EGFRvIII + tumor areas.</s><s>In addition, we performed double immunofluorescence staining with EGFRvIII and phospho c-SRC Y216 antibodies demonstrating coexpression of both proteins (Fig. <ref type="figure" target="#fig_3">4E</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Angiogenic and Aggressive Tumor Growth Mediated by EGFRvIII Is Dependent on c-SRC</head><p><s>To investigate whether c-SRC is responsible for the EGFRvIIImediated secretion of angiogenic factors, we performed in vitro angiogenesis arrays and blocked c-SRC activation in P3 EGFRvIII + cells by either overexpressing a c-SRC shRNA construct (shSRC; Supplementary material, Fig. <ref type="figure" target="#fig_6">S6</ref>) or using anti-Src small molecule inhibitors.</s><s>Additionally, we overexpressed a constitutively active Src (Src + ; Supplementary material, Fig. <ref type="figure" target="#fig_6">S6</ref>) in P3 control cells.</s><s>Both EGFRvIII + and Src + P3 cells secreted higher levels of VEGFA than P3 control cells, and suppression of c-SRC activity using shSRC, dasatinib, or saracatinib counteracted or reduced the enhanced VEGFA secretion (Supplementary material, Fig. <ref type="figure">S7</ref>).</s><s>Next, we implanted P3EGFRvIII + shSrc and control cells orthotopically into nude rats.</s><s>Animals harboring EGFRvIII + shSRC tumors survived significantly longer than those harboring control tumors (Fig. <ref type="figure" target="#fig_5">5A</ref>).</s><s>Importantly, EGFRvIII + shSRC tumors did not show contrast enhancement on T1-weighted MRI, while control tumors did as expected (Fig. <ref type="figure" target="#fig_5">5B</ref>).</s></p><p><s>To verify that angiogenesis was reduced in EGFRvIII + shSRC compared with EGFRvIII + shRNA control P3 tumors, we performed histology and vWF immunohistochemistry on tissue specimens.</s><s>Control tumors showed significantly greater vessel-area staining than EGFRvIII + shSRC tumors (Fig. <ref type="figure" target="#fig_5">5C  and D</ref>).</s><s>Furthermore, we determined if the EGFRvIII + shSRC tumors exhibited a more invasive behavior compared with control tumors because Src has previously been shown to be involved in invasion. <ref type="bibr" target="#b35">35,</ref><ref type="bibr" target="#b37">37</ref></s><s>Interestingly, immunostaining for human nestin showed significantly greater invasion in EGFRvIII + shSRC tumors compared with controls (Fig. <ref type="figure" target="#fig_5">5C and E</ref>).</s></p><p><s>To further evaluate the differences in angiogenesis at the molecular level, we performed Western blots on lysates derived from P3 EGFRvIII + shSRC and EGFRvIII + shRNA control P3 tumors.</s><s>Indeed, c-SRC expression and activation was reduced in EGFRvIII + shSRC specimens compared with controls, and this correlated with the level of bFGF and VEGFA expression (Fig. <ref type="figure" target="#fig_5">5F</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Constitutively Active Src Induces Angiogenesis in EGFRvIII-negative Tumors in Vivo</head><p><s>Since EGFRvIII appeared to be dependent on c-SRC in mediating angiogenesis and aggressive tumor growth, we hypothesized that P3 cells could become angiogenic without EGFRvIII as long as c-SRC was overexpressed and active.</s><s>Accordingly, we sorted and prepared P3 Src + and corresponding vector control cells for orthotopic injection into nude rats.</s><s>P3 control animals lived significantly longer than those harboring Src + tumors (Fig. <ref type="figure" target="#fig_6">6A</ref>).</s><s>Furthermore, we performed MR imaging that showed more heterogeneous tumors in the Src + group compared with controls on T2-weighted images.</s><s>Focal loss of the hyperintense signal within Src + tumors may represent intratumoral microbleeding indicative of increased vascular permeability.</s><s>In addition, Src + P3 tumors showed increased contrast enhancement compared with control tumors (Fig. <ref type="figure" target="#fig_6">6B</ref>).</s></p><p><s>We also performed histology and vWF IHC on xenograft tumors to further characterize the angiogenic and aggressive characteristics of Src + P3 tumors.</s><s>Src + tumors showed significantly greater vessel-area staining than controls, indicating increased angiogenesis (Fig. <ref type="figure" target="#fig_6">6C and D</ref>).</s><s>Microbleeding around vessels was detected on hematoxylin and eosin (H&amp;E) sections and verified the MRI findings (data not shown).</s><s>We then investigated the invasive properties of P3 Src + and control tumors.</s><s>Notably, human nestin IHC revealed significantly greater invasion in control specimens compared with Src + tumor specimens (Fig. <ref type="figure" target="#fig_6">6C and E</ref>).</s><s>To confirm the induction of angiogenesis by Src + P3 tumors at the molecular level, we performed Western blots and found that upregulation of VEGFA was indeed dependent on c-SRC overexpression and activation (Fig. <ref type="figure" target="#fig_6">6F</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In the present study, we identified distinct clonal evolution patterns of EGFR amplification and EGFRvIII mutations in a small cohort of patient GBMs.</s><s>DNA breakpoint analysis revealed the emergence of distinct EGFRvIII mutations in different regions within the same tumor.</s><s>In contrast, EGFR amplification/gain was present in all tumor areas, which indicates that EGFR amplification is an early event in tumorigenesis, while EGFRvIII emerges later during tumor progression.</s><s>Intratumoral heterogeneity was also recently observed for the less prominent EGFRvII mutation using single-cell nucleus sequencing. <ref type="bibr" target="#b9">10</ref></s><s>umor heterogeneity can also emerge within a therapeutic setting, as was recently shown for the EGFRvIII mutation: Treatment of EGFRvIII-mutated GBM cells with EGFR tyrosine kinase inhibitors resulted in drug resistance due to elimination of EGFRvIII from extrachromosomal DNA, <ref type="bibr" target="#b22">22</ref> underscoring the complexity of tumor heterogeneity.</s></p><p><s>To establish biological relevance for the sequenced EGFR aberrations, we investigated the functions of wtEGFR and EGFRvIII in human GBM xenografts in vivo.</s><s>EGFRvIII + and wtEGFR + -EGFRvIII + tumors grew faster and more angiogenic compared with control and wtEGFR + tumors.</s><s>A more aggressive phenotype mediated by EGFRvIII has also been observed in U87 cells. <ref type="bibr" target="#b38">38,</ref><ref type="bibr" target="#b39">39</ref></s><s>However, we also found a substantial increase in angiogenesis in EGFRvIII + and wtEGFR + EGFRvIII + tumors in addition to the enhanced tumor growth.</s><s>Indeed, EGFRvIII has been linked to angiogenesis in other animal models <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b18">18,</ref><ref type="bibr" target="#b20">20</ref> and in a Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma study investigating patient tumors by perfusion MRI. <ref type="bibr" target="#b40">40</ref></s><s>We further confirmed the angiogenic capacity of EGFRvIII in patient samples by demonstrating that EGFRvIII + tumor cells are more frequently found around microvascular proliferations/dilated vessels compared with EGFRvIII 2 /pEGFR + tumor cells representing those with wtEGFR activation.</s></p><p><s>Interestingly, we detected a decrease in invasion by EGFR-vIII, while wtEGFR instead enhanced invasion and concomitantly reduced angiogenic tumor growth in our xenograft models.</s><s>We have previously shown that EGFR amplification mediates invasion independent of angiogenesis, <ref type="bibr" target="#b26">26</ref> and we confirmed here in another model system that wtEGFR does not</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma</head><p><s>promote GBM angiogenesis but rather enhances invasion.</s><s>Our results further support the notion that EGFR status has an important impact on the balance between invasive and angiogenic growth that culminates in intratumoral heterogeneity.</s></p><p><s>The distinct functions of wtEGFR and EGFRvIII also suggested a difference in downstream signaling.</s><s>Compared with EGFR-vIII, wtEGFR showed a stronger association with adaptor proteins related to classical RTK signaling.</s><s>In contrast, we observed an enrichment of SFK signaling in EGFRvIII + cells compared with wtEGFR + cells.</s><s>Specifically, EGFRvIII tumors upregulated c-SRC.</s><s>Meanwhile, other SFKs including c-YES and FYN were not expressed by the tumor cells, and LYN was expressed-but not specifically upregulated-in EGFRvIII + tumor cells.</s><s>Although previous findings have demonstrated that c-SRC interacts with EGFR in GBM cells, <ref type="bibr" target="#b35">35,</ref><ref type="bibr" target="#b41">41</ref> we showed here that this interaction is specific for EGFRvIII.</s></p><p><s>We verified that the angiogenic capacity of the EGFRvIII + tumors was dependent on c-SRC by performing functional experiments.</s><s>The angiogenesis-promoting effects of Src activation have indeed been shown in GBM cells in addition to other cell lines and tumor models including those of ovarian and colon cancer, <ref type="bibr">42 -44</ref> but this has not been previously linked to EGFRvIII signaling.</s></p><p><s>In contrast to other findings implicating Src activation in tumor invasion, <ref type="bibr" target="#b35">35,</ref><ref type="bibr" target="#b37">37,</ref><ref type="bibr" target="#b45">45</ref> we propose a mechanism of c-SRC activation that is directly linked to oncogenic EGFRvIII signaling and promotes angiogenic and aggressive tumor growth.</s><s>In fact, we found significantly reduced invasion in EGFRvIII 2 Src + tumor specimens and significantly increased invasion in EGFRvIII + shSrc tumor specimens.</s><s>We attribute the discrepancies mainly to the notion that constitutive Src activation, as mediated by EGFRvIII, might produce a different biological response compared with nonconstitutive Src activation by other means.</s><s>We did not observe high levels of SFK activation in wtEGFR + cells in our model system, nor did we find substantial SFK activation in several GBM xenografts with EGFR amplification (unpublished results).</s><s>SFK activation, and specifically activation of c-SRC, appears to be mediated by EGFRvIII and not wtEGFR.</s></p><p><s>In conclusion, the presented work suggests that sequential evolutionary events of EGFR amplification and EGFRvIII mutations together contribute to the progression of primary GBM from an invasive tumor to one that is highly angiogenic.</s><s>Furthermore, our results reveal that c-SRC mediates the angiogenic tumor growth downstream of EGFRvIII and that targeting this distinct signaling axis may be an attractive approach for clinical intervention of GBM.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>The evolutionary dynamics of EGFR amplification and EGFRvIII mutation in patient glioblastoma (GBM).</s><s>(A) MRI of GBM patients sp54 and sp55 with schematic illustration of tumor sampling.</s><s>EGFR amplification is detected in all samples from both patients, while EGFRvIII mutations and the point mutation EGFR R222C are found only in distinct tumor areas.</s><s>(B) Deletions within the EGFR.</s><s>Any PCR products shorter than the expected amplicon size were subjected to capillary sequencing for identification of deletion breakpoints (indicated by arrowheads).</s><s>Asterisks indicate that the given sequence is antisense.</s><s>(C) Molecular clock analysis of tumor samples from patients sp54 and sp55 demonstrate evolution of EGFRvIII mutations and R222C point mutation over time.</s></p></div></figDesc><graphic coords="3,59.02,332.79,474.75,310.45" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. EGFRvIII + and wtEGFR + EGFRvIII + tumors show greater contrast enhancement and vascular permeability and are more aggressive than control and wtEGFR + tumors.</s><s>(A) Kaplan-Meier survival curves of EGFRvIII + , wtEGFR + EGFRvIII + , wtEGFR + , and control P3 xenografts show that the difference in survival between EGFRvIII + /wtEGFR + EGFRvIII + and control/wtEGFR + tumors is statistically significant (log-rank, P , .01/P , .01);</s><s>n ¼ 4. (B) T2-and T1-weighted w/contrast MRIs.</s><s>(C) Blood flow (F), blood volume (BV), blood-to-tissue transfer coefficient (Ktrans), and interstitial space (Ve) were obtained by pharmacokinetic analysis of DCE-MRI data.</s><s>(D) Quantification of all parameters revealed significantly larger values in the EGFRvIII + and wtEGFR + EGFRvIII + groups compared with wtEGFR + and control groups in P3 xenografts (P , .0001).</s><s>Data are represented as mean+standard errors; n ≥ 3.</s></p></div></figDesc><graphic coords="5,56.19,85.32,480.76,470.44" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. EGFRvIII + and wtEGFR + EGFRvIII + tumors promote angiogenesis, while wtEGFR + tumors do not.</s><s>(A) H&amp;E and immunostaining for vWF show typical microvascular proliferation (arrows), indicating angiogenic tumor growth in the EGFRvIII + and wtEGFR + EGFRvIII + groups from P3 xenografts.</s><s>wtEGFR + and control tumors show normal vasculature.</s><s>(B) Vessel area fractions as indicated by vWF immunostaining.</s><s>Quantification was performed at 200× magnification.</s><s>Values represent mean+SD.</s><s>* P , .05;</s><s>** P , .01:</s><s>**** P , .001;</s><s>n ¼ 10.</s><s>Scale bars 50 mm.</s><s>(C) Western blot of EGFR, pEGFR, and angiogenic factors showing upregulation of HIF1A,VEGF, ANGPT1, and ANGPT2 in EGFRvIII + and wtEGFR + EGFRvIII + tumors compared with both wtEGFR + and controls tumors.</s><s>(D) Immunohistochemical staining of EGFRvIII + GBM biopsies with antibodies against EGFRvIII, pEGFR, and vWF.</s><s>Scale bars, 50 mm.</s><s>(E) Area fraction of vascular elements immunostained with vWF from EGFRvIII + vs EGFRvIII 2 /pEGFR + areas from 3 different patients.</s><s>Quantification was performed at 200× magnification.</s><s>**** P , .001;</s><s>n ¼ 15.</s><s>Values represent mean+SD.</s></p></div></figDesc><graphic coords="6,84.54,85.32,420.66,484.38" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig. 4. c-SRC is upregulated and activated in EGFRvIII + tumor cells.</s><s>(A) Network analysis of the protein pool was identified to accumulate .2-fold in the stimulated wtEGFR versus unstimulated wtEGFR interactome (left) versus network analysis of the protein pool identified to accumulate .2-fold in the stimulated EGFRvIII vs wtEGFR interactome (right).</s><s>Note that the SFKs YES, and FYN are implicated in the EGFRvIII interactome while they are not implicated in the wtEGFR interactome.</s><s>(B) Immunohistochemical stainings for SFKs in P3 xenograft tissue specimens.</s><s>(C) Western blot of in vivo lysates from control, wtEGFR + , and EGFRvIII + P3 tumor specimens.</s><s>(D) Immunostaining of glioblastoma (GBM) biopsies with antibodies against EGFRvIII and c-Src.</s><s>(E) Double immune-fluorescence staining of GBM biopsies with antibodies against EGFRvIII (green) and c-SrcY216 (red).</s></p></div></figDesc><graphic coords="7,76.20,85.32,441.58,578.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig. 5 .</head><label>5</label><figDesc><div><p><s>Fig. 5. Aggressive tumor growth and angiogenesis, mediated by EGFRvIII, are dependent on c-SRC.</s><s>(A) Kaplan-Meier survival curve showing survival of rats with P3 EGFRvIII + shSRC and EGFRvIII + shRNA control tumors.</s><s>The difference in survival is statistically significant (log-rank; P , .05).</s><s>n ¼ 4 (B) T2-and T1-weighted MRIs of control and treated tumors with and without contrast.</s><s>(C) H&amp;E and immunostaining for vWF (tumor center) show typical microvascular proliferation, indicating angiogenic tumor growth in EGFRvIII + control tumors.</s><s>EGFRvIII + shSRC tumors, meanwhile, show significantly less angiogenesis.</s><s>H&amp;E and immunostaining for human nestin (tumor border) show significantly more invasive growth in the EGFRvIII + shSRC tumors compared with control tumors.</s><s>(D) Quantification of vessel area in vWF immunostained sections was performed at 200× magnification (n ¼ 10); ** P , .01. (E) Quantification of nestin + cells was performed at 400× magnification (n ¼ 10); ** P , .01. (F) Western blot of EGFRvIII + control and EGFRvIII + shSRC tumor lysates.</s></p></div></figDesc><graphic coords="9,59.02,85.32,474.75,466.07" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Fig. 6 .</head><label>6</label><figDesc><div><p><s>Fig. 6.</s><s>Constitutively active Src induces angiogenesis in EGFRvIII-negative P3 tumors in vivo.</s><s>(A) Kaplan-Meier survival curve showing survival of rats with P3 Src + and control tumors.</s><s>The difference in survival is statistically significant (log-rank; P , .05).</s><s>n ≥ 4 (B) T2-and T1-weighted MRIs of control and treated tumors with and without contrast.</s><s>(C) H&amp;E and immunostaining for vWF (tumor center) show microvascular proliferation, indicating angiogenic tumor growth in Src + tumors.</s><s>Control tumors, meanwhile, show significantly less angiogenesis.</s><s>H&amp;E and immunostaining for human nestin (tumor border) show significantly less invasive growth in the Src + tumors than in control tumors (P , .001).</s><s>(D) Quantification of vessel area in vWF immunostained sections was performed at 200× magnification (n ¼ 10); ** P , .01. (E) Quantification of nestin + cells was performed at 400× magnification (n ¼ 10); **** P , .001.</s><s>(F) Western blot of control, Src + , wtEGFR + and EGFRvIII + tumor lysates.</s></p></div></figDesc><graphic coords="10,59.02,85.32,474.75,423.89" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma Eskilsson et al.: Evolution and functions of EGFRs in glioblastoma Multimodal Imaging Reveals Increased Angiogenic and Aggressive Growth of EGFRvIII + and wtEGFR + EGFRvIII + Tumors</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Neuro-Oncology</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We thank I. Gavlen, B. Hansen, E. Fick, P.Ø.</s><s>Sakariassen, and B. Leirvaag for expert technical assistance and the Molecular Imaging Center (MIC) in Bergen, Norway, for technical support.</s><s>We thank Christel Herold-Mende, University of Heidelberg, Germany, for providing the NCH421k cells.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head><p><s>Supplementary material is available at Neuro-Oncology Journal online (http://neuro-oncology.oxfordjournals.org/).</s><s>Conflict of interest statement.</s><s>The authors declare that they have no conflict of interests.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Amplified cellular oncogenes in neoplasms of the human central nervous system</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Fuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Bigner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mutat Res</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="299" to="306" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Structural alterations of the epidermal growth factor receptor gene in human gliomas</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ruppert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Bigner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2965" to="2969" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Scheidenhelm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="7429" to="7437" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors</title>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dutra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="9" to="21" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Tumour heterogeneity and cancer cell plasticity</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Meacham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Morrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">501</biblScope>
			<biblScope unit="issue">7467</biblScope>
			<biblScope unit="page" from="328" to="337" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Tumour heterogeneity in the clinic</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Bedard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ratain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Siu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">501</biblScope>
			<biblScope unit="issue">7467</biblScope>
			<biblScope unit="page" from="355" to="364" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Novel points of attack for targeted cancer therapy</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Rosland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Engelsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Basic Clin Pharmacol Toxicol</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="9" to="18" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sottoriva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Spiteri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Piccirillo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="4009" to="4014" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tirosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Trombetta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="issue">6190</biblScope>
			<biblScope unit="page" from="1396" to="1401" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Maire</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="956" to="971" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Tkach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Berezin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Poulsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="643" to="653" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3&apos;-kinase and distinct from that induced by hypoxia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Maity</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'rourke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="5879" to="5886" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells</title>
		<author>
			<persName><forename type="first">N</forename><surname>Magnus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Garnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="815" to="818" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2</title>
		<author>
			<persName><forename type="first">T</forename><surname>Martens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Laabs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Gunther</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="5447" to="5458" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Guillamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Bouard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Valable</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="3697" to="3704" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">EGFRvIII promotes glioma angiogenesis and growth through the NF-kB, interleukin-8 pathway</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bonavia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Inda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vandenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">36</biblScope>
			<biblScope unit="page" from="4054" to="4066" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway</title>
		<author>
			<persName><forename type="first">K</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Gullick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1322" to="1329" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">Evolution and functions of EGFRs in glioblastoma</title>
		<author>
			<persName><surname>Eskilsson</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="7125" to="7134" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180</title>
		<author>
			<persName><forename type="first">H</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vuori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="2504" to="2512" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Katanasaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kodera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kitamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Morimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Koizumi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">31</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Constitutive EGFR signaling confers a motile phenotype to neural stem cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Boockvar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kapitonov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kapoor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Neurosci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1116" to="1130" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Nathanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mottahedeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="issue">6166</biblScope>
			<biblScope unit="page" from="72" to="76" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Angiogenesisindependent tumor growth mediated by stem-like cancer cells</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Sakariassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Prestegarden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">44</biblScope>
			<biblScope unit="page" from="16466" to="16471" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Differentiation therapy exerts antitumor effects on stem-like glioma cells</title>
		<author>
			<persName><forename type="first">B</forename><surname>Campos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Farhadi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2715" to="2728" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF</title>
		<author>
			<persName><forename type="first">N</forename><surname>Podergajs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Brekka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Radlwimmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiol Oncol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="330" to="337" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Talasila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Soentgerath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Euskirchen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="683" to="698" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Characterization of the EGFR interactome reveals associated protein complex networks and intracellular receptor dynamics</title>
		<author>
			<persName><forename type="first">S</forename><surname>Foerster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kacprowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Dhople</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proteomics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="3131" to="3144" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vectormediated suicide gene therapy</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Huszthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Giroglou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Tsinkalovsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">e6314</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma</title>
		<author>
			<persName><forename type="first">O</forename><surname>Keunen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oudin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3749" to="3754" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Single-channel blind estimation of arterial input function and tissue impulse response in DCE-MRI</title>
		<author>
			<persName><forename type="first">T</forename><surname>Taxt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jirik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Rygh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">IEEE Trans Biomed Eng</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1012" to="1021" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sottoriva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Spiteri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tavare</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="41" to="49" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Piccirillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Spiteri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sottoriva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="194" to="202" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nika</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="547" to="559" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway</title>
		<author>
			<persName><forename type="first">A</forename><surname>Glading</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lauffenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wells</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">275</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="2390" to="2398" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cvrljevic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="6889" to="6898" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Cellular functions regulated by Src family kinases</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Brugge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rev Cell Dev Bio</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="513" to="609" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Del Maestro RF. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions</title>
		<author>
			<persName><forename type="first">A</forename><surname>Angers-Loustau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Werbowetski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Res</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="595" to="605" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity</title>
		<author>
			<persName><forename type="first">R</forename><surname>Nishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">D</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Harmon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="7727" to="7731" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nagane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Coufal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bogler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Cavenee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="5079" to="5086" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Tykocinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Kapoor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="613" to="623" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Activation of Src induces mitochondrial localisation of de2 -7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Cvrljevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Akhavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Sci</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="2938" to="2950" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Pt 17</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Wiener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Kruzelock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Bucana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Bast</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Gallick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="2164" to="2170" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">U</forename><surname>Parikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Staley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Gallick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surgery</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="501" to="507" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mukhopadhyay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tsiokas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X-M</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Brugge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Sukhatme</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="issue">6532</biblScope>
			<biblScope unit="page" from="577" to="581" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion</title>
		<author>
			<persName><forename type="first">D</forename><surname>Huveldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Lewis-Tuffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Carlson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e56505</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
